Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
Phase II study, randomized, open-label, multicentric, willing to establish the benefit of
pursuing chemotherapy beyond 6 weeks for non progressive patients. The study will proceed in
two successive phases :
- non randomized phase in which all patients will undergo chemotherapy
- second phase in which only non progressive patients are going to be randomized
("discontinuation design"). Patients that will show progression in their disease during
the first 6 weeks will be released of the study